-
WilmerHale Advises Werewolf Therapeutics in $72M Series B Financing
1.8.2021On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing.
-
2020 IPO, Venture Capital and M&A Reports
6.29.2020WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2020 M&A Report
6.29.2020The 2020 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2020 IPO Report
6.29.2020The 2020 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
2020 Venture Capital Report
6.29.2020The 2020 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
COVID-19: Understanding the Paycheck Protection Loan Program and Expansion of the Emergency Economic Injury Disaster Loan Programs Under the CARES Act
3.30.2020On Friday, March 27, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) became law.
-
Recent Venture Financings as Company Counsel: 2020
3.17.2020In 2019, we served as counsel in more than 225 venture financings raising in excess of $5 billion, including some of the largest and most prominent deals of the year.
-
LMG Life Sciences 2019 Recognizes WilmerHale as a Leading Law Firm for Life Sciences
10.2.2019WilmerHale and 18 of its lawyers are once again recognized among the nation’s leading life sciences law firms and lawyers in the 2019 edition of LMG Life Sciences.
-
LMG Life Sciences Names WilmerHale General Patent Litigation Firm of the Year and Intellectual Property Firm of the Year
9.24.2019WilmerHale earned two Firm of the Year distinctions at the LMG Life Sciences Awards 2019.
-
LMG Life Sciences Awards 2019 Announces Shortlists, WilmerHale Featured in 14 Categories
8.21.2019LMG Life Sciences has named WilmerHale and six of its partners to its 2019 award shortlists in a total of 14 categories.
-
2019 IPO, Venture Capital and M&A Reports
6.4.2019WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2019 Venture Capital Report
6.4.2019The 2019 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
-
2019 IPO Report
6.4.2019The 2019 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.
-
2019 M&A Report
6.4.2019The 2019 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
WilmerHale Advises Inozyme Pharma in $67 Million Series A2 Financing
4.17.2019Biotechnology company Inozyme Pharma, Inc. announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.
